? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Clinical Trial Results. org Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation Eric Eisenstein, DBA; Kevin Anstrom,
Can we prevent stent restenosis after coronary stent implantation
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Update on the Medical Management of Acute Coronary Syndrome.
PCI VS CABG JOURNAL REVIEW
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Patient Beliefs Regarding Benefits of Percutaneous Coronary Intervention in Chronic Stable Angina My Summer Research Project of 2014 Carla Lauture, of.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Total Occlusion Study of Canada (TOSCA-2) Trial
Copyright © 2014 American Medical Association. All rights reserved.
CABG in diabetics: surgical aspects
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
“Per Protocol” Definitions of Stent Thrombosis
Clinical need for determination of vulnerable plaques
Successful CTO PCI Associated with Lower Mortality Risk
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Catheter-Based Treatment of Coronary Artery Disease
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Glenn N. Levine et al. JACC 2016;68:
Recurrent Angina: New Tools for an Old Problem
Terms of Use. Terms of Use.
Section 5: Intervention and drug therapy
American College of Cardiology Presented by Dr. Stephan Windecker
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Giuseppe Biondi Zoccai, MD
Nat. Rev. Cardiol. doi: /nrcardio
BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
American College of Cardiology Presented by Dr. Michel R. Le May
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Potential mechanisms whereby statins may reduce the risk of stroke
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
(A) Meta-analysis of repeat revascularisation in randomised trials.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Section C: Clinical trial update: Oral antiplatelet therapy
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1

Background & objectives  Early randomized trials of percutaneous intervention (PCI) vs medical therapy alone and some meta-analyses demonstrated greater reduction in angina with PCI than with medical therapy alone.  However, prior meta-analyses were based on PCI and medical therapy that do not reflect current interventional practice.  Meta-analysis of contemporary trials has been performed to compare initial coronary stent implantation and medical therapy vs medical therapy alone to determine the effect on death, nonfatal myocardial infarction, and persistent angina. 2

Stergiopoulos and Brown. Arch Intern Med. 2012;172(4): Effect of initial stent implantation vs medical management for nonfatal myocardial infarction non fatal MI Meta-analysis of eight contemporary trials (7229 patients, 4.3 years follow-up)

Stergiopoulos and Brown. Arch Intern Med. 2012;172(4): Effect of initial stent implantation vs medical management for persistent angina during follow-up Meta-analysis of eight contemporary trials (7229 patients, 4.3 years follow -up)

Implantation of a stent for the treatment of stable coronary artery disease (CAD) does not lower the risk of death, nor does PCI reduce the risk of nonfatal MI or angina when compared with optimal medical therapy. The failure of stent implantation to reduce the risk of death or MI compared with medical therapy reinforces current concepts of the underlying pathophysiologic characteristics of atherosclerosis as a diffuse process leading to vulnerable plaque disruption and subsequent coronary thrombosis, MI, and death. The findings support recommendations that stable CAD patients should be treated with medical therapy rather than first undergoing stent implantation. Implications